Literature DB >> 29713787

Cognitive profile of ketamine-dependent patients compared with methamphetamine-dependent patients and healthy controls.

Liang-Jen Wang1,2, Chih-Ken Chen2,3, Shih-Ku Lin4,5, Yi-Chih Chen2,3, Ke Xu6, Ming-Chyi Huang7,8.   

Abstract

BACKGROUND: Ketamine has emerged as a major substance of abuse worldwide and has been listed with methamphetamine (METH) as two of the most widely available illicit substances in Taiwan. Only a few studies have examined the long-term consequences of chronic and heavy ketamine abuse. We compared the cognitive function of ketamine-dependent patients with that of METH-dependent patients and healthy controls.
METHODS: We recruited 165 participants (58 ketamine-dependent and 49 METH-dependent patients who sought treatment and 58 healthy controls) and evaluated them by using a cognitive test battery, the Brief Assessment of Cognition in Schizophrenia, with scores being estimated in reference to normative data in general population.
RESULTS: The ketamine-dependent patients had significantly poorer performance than did the controls in many cognitive tests, including verbal memory, motor speed, verbal fluency, and attention and processing speed, and the battery as a whole. METH-dependent patients exhibited poorer function in motor speed, verbal fluency, and attention and processing speed. The ketamine group performed poorer than did METH group in the domains of verbal memory, working memory, and attention and processing speed and the composite battery scores. A previous experience of ketamine-induced psychotomimetic symptoms, using higher doses of ketamine, and longer abstinence appeared to be associated with performance in some tests; however, the significance disappeared after multiple comparison correction.
CONCLUSIONS: The ketamine-dependent patients had impaired cognitive function, and METH-dependent patients exhibited intermediate performance between ketamine-dependent patients and healthy controls. Given the growing population of ketamine abusers, public education on the cognitive consequences should be provided.

Entities:  

Keywords:  Cognition; Ketamine; Methamphetamine; Psychosis; Substance dependence

Mesh:

Substances:

Year:  2018        PMID: 29713787     DOI: 10.1007/s00213-018-4910-z

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  56 in total

1.  Working memory in cigarette smokers: comparison to non-smokers and effects of abstinence.

Authors:  Adrianna Mendrek; John Monterosso; Sara L Simon; Murray Jarvik; Arthur Brody; Richard Olmstead; Catherine P Domier; Mark S Cohen; Monique Ernst; Edythe D London
Journal:  Addict Behav       Date:  2005-07-11       Impact factor: 3.913

2.  Effects of cigarette smoking and abstinence on Stroop task performance.

Authors:  Catherine P Domier; John R Monterosso; Arthur L Brody; Sara L Simon; Adrianna Mendrek; Richard Olmstead; Murray E Jarvik; Mark S Cohen; Edythe D London
Journal:  Psychopharmacology (Berl)       Date:  2007-07-19       Impact factor: 4.530

Review 3.  A review of the clinical pharmacology of methamphetamine.

Authors:  Christopher C Cruickshank; Kyle R Dyer
Journal:  Addiction       Date:  2009-04-29       Impact factor: 6.526

4.  Chronic ketamine exposure induces permanent impairment of brain functions in adolescent cynomolgus monkeys.

Authors:  Lin Sun; Qi Li; Qing Li; Yuzhe Zhang; Dexiang Liu; Hong Jiang; Fang Pan; David T Yew
Journal:  Addict Biol       Date:  2012-11-12       Impact factor: 4.280

5.  NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia.

Authors:  S Kapur; P Seeman
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

6.  Patterns of use and harms associated with non-medical ketamine use.

Authors:  Paul Dillon; Jan Copeland; Karl Jansen
Journal:  Drug Alcohol Depend       Date:  2003-01-24       Impact factor: 4.492

Review 7.  Imaging of striatal dopamine release elicited with NMDA antagonists: is there anything there to be seen?

Authors:  Eugenii A Rabiner
Journal:  J Psychopharmacol       Date:  2007-05       Impact factor: 4.153

8.  Long-term effects of ketamine: evidence for a persisting impairment of source memory in recreational users.

Authors:  Celia J A Morgan; Marcio Riccelli; Charles H Maitland; H Valerie Curran
Journal:  Drug Alcohol Depend       Date:  2004-09-06       Impact factor: 4.492

9.  Emotion dysregulation and amygdala dopamine D2-type receptor availability in methamphetamine users.

Authors:  Kyoji Okita; Dara G Ghahremani; Doris E Payer; Chelsea L Robertson; Andy C Dean; Mark A Mandelkern; Edythe D London
Journal:  Drug Alcohol Depend       Date:  2016-02-12       Impact factor: 4.492

Review 10.  An evaluation of the evidence that methamphetamine abuse causes cognitive decline in humans.

Authors:  Andy C Dean; Stephanie M Groman; Angelica M Morales; Edythe D London
Journal:  Neuropsychopharmacology       Date:  2012-09-05       Impact factor: 7.853

View more
  4 in total

1.  Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers.

Authors:  Dmitriy Matveychuk; Rejish K Thomas; Jennifer Swainson; Atul Khullar; Mary-Anne MacKay; Glen B Baker; Serdar M Dursun
Journal:  Ther Adv Psychopharmacol       Date:  2020-05-11

2.  Difference in long-term relapse rates between youths with ketamine use and those with stimulants use.

Authors:  Liang-Jen Wang; Mei-Yen Chen; Chin-Yin Lin; Mian-Yoon Chong; Wen-Jiun Chou; Yu-Han You; Chih-Pu Tsai; Yi-Syuan Chen; Shing-Fang Lu
Journal:  Subst Abuse Treat Prev Policy       Date:  2018-12-22

3.  Methamphetamine Users Show No Behavioral Deficits in Response Selection After Protracted Abstinence.

Authors:  Wiebke Bensmann; Julia Ernst; Marion Rädle; Antje Opitz; Christian Beste; Ann-Kathrin Stock
Journal:  Front Psychiatry       Date:  2019-11-19       Impact factor: 4.157

4.  Chronic ketamine abuse is associated with orexin-A reduction and ACTH elevation.

Authors:  Ming-Chyi Huang; Chun-Hsin Chen; Lian-Yu Chen; Hu-Ming Chang; Chih-Ken Chen; Shih-Ku Lin; Ke Xu
Journal:  Psychopharmacology (Berl)       Date:  2019-08-03       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.